CEACAM5 and adenocarcinoma: Applying anti-CEA CAR-T cells in CEA+ adenocarcinoma with liver metastasis (NCT02416466 and NCT02850536) intraarterially administered, improved the delivery of cells into the metastasis and reduced cytokine release syndrome (CRS) [58].